Parkinson’s disease. Focus on early stages
Open Access
- 4 July 2023
- journal article
- review article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (3) , 95-103
Abstract
The review presents current data on the peculiarities of the neurodegenerative process in the early stages of Parkinson’s disease (PD) and considers the hypothesis of the presence of body-first and brain-first subtypes of the disease onset. The earliest manifestations of the disease include symptoms such as parasomnia, constipation, hyposmia, anxiety-depressive disorder, daytime sleepiness, color perception changes, cognitive dysfunction, and mild motor manifestations. The diagnosis of PD can be made when characteristic motor manifestations occur: hypokinesia, rest tremor, muscle rigidity. Substantia nigra ultrasound, magnetic resonance imaging in SWI mode, and functional neuroimaging methods are used as confirmatory methods. The approach to the treatment of early stages of PD is age dependent. Patients over 70 years of age are recommended to start therapy with levodopa; younger patients – with dopamine receptor agonists (ADR), amantadines, MAO-B inhibitors. The mechanisms of ADR action, the possibility of their influence on the motor and non-motor symptoms of PD are analyzed. A special place is given to piribedil, which, due to the dual mechanism of action, has a positive effect on cognitive functions, depression, apathy, as well as a minimal effect on daytime sleepiness.Keywords
This publication has 100 references indexed in Scilit:
- MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCIMovement Disorders, 2011
- Noradrenaline and Parkinson's DiseaseFrontiers in Systems Neuroscience, 2011
- Mild cognitive impairment in Parkinson diseaseNeurology, 2010
- Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinsonʼs DiseaseDrugs & Aging, 2010
- Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in MicePLOS ONE, 2010
- Neuropsychiatric symptoms in Parkinson's diseaseMovement Disorders, 2009
- Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's diseaseMovement Disorders, 2009
- Behavioural Adverse Effects of Dopaminergic Treatments in Parkinsonʼs DiseaseDrug Safety, 2009
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology, 2007
- Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?Drugs & Aging, 2001